<img alt="" src="https://secure.lazy8krti.com/218831.png" style="display:none;">
Request a proposal

Living with Uterine Fibroids (UF)

Published July 2022, US report

"Living with Uterine Fibroids" is a syndicated patient report which offers low-cost, high-value quantitative and qualitative insights into patient attitudes and behaviour.

We recognise pharma brands need access to unique insights if they are to develop effective products and treatments and relevant communications messages. Living with UF is designed to provide an in-depth understanding of the UF disease patient journey, from diagnosis through treatment and ongoing management, unveiling patients attitudes, needs and treatment programmes.

Gain an in-depth understanding of:

  • The presentation history and diagnosis pathway from the perspective of patients
  • Patient attitudes to their uterine fibroids and the impact on their lives
  • What patients are currently doing to cope with their condition, including treatments taken, satisfaction levels and use of OTC treatment
  • Attitudes and behaviours with regard to treatment switching and adherence
  • Attitudes to interactions with healthcare professionals
  • Patient wishes and unmet needs
  • Patients’ sources of information and use of digital tools, such as apps and social media

Methodology 

Living with Uterine Fibroids US

Methodology

Quant: 40-minute online interviews with UF patients
Qual: 40-minute qualitative telephone interviews with UF patients, including patient diary task 1 week before the interview
Countries US
Total 

USA110
Sample considerations
  • All patients were required to be diagnosed with uterine fibroids (UF) by a doctor and be premenopausal
  • Quotas were set on patients’ history of UF surgery:
    35% of patients were required to have undergone surgery for their fibroids
    65% of patients were required not to have undergone surgery for their fibroids
    Patients who had undergone a hysterectomy were excluded from this research
  • All patients were required to currently receive prescribed treatment for their UF & have experienced heavy menstrual bleeding due to their UF
  • Criteria were set to recruit specific % of patients in particular groups to allow for robust analysis of these patient groups.
  • Age quotas were as follows:
    Age 25-40: 65%
    Age 41-50: 35%

 

Request more information on Living With
mariel-web-image

Mariel Metcalfe

Director, Head of Living With

Mariel is the Head of Living With and has 18 years of pharmaceutical market research experience in a wide variety of qualitative and quantitative methodologies, including global tracker research and segmentation. She has worked in a variety of therapy areas including infectious, autoimmune, respiratory and metabolic diseases. Mariel has extensive experience in patient insights and is committed to bringing the patient voice to life. She has written multiple articles and hosts the podcast ‘Living with Chronic Illness’ which is designed to give a voice to patients suffering from chronic conditions.

mariel.metcalfe@researchpartnership.com